Prednisone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Prednisone: From Autoimmune and Inflammatory Diseases to Alopecia Areata
One-Sentence Summary
Prednisone is a systemic glucocorticoid originally used for autoimmune and inflammatory conditions (such as Crohn disease and adrenocortical insufficiency) and for certain leukaemias. The TxGNN model predicts it may be effective for alopecia areata, with no registered clinical trials but 20 publications currently supporting this direction, including one randomised controlled trial (prednisone combined with methotrexate).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, adrenocortical insufficiency, Crohn disease and inflammatory bowel disease, acute lymphoblastic leukaemia, eosinophilic pneumonia, congenital adrenal hyperplasia (the Singapore licence text for the approved indication is not available) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, prednisone is a systemic glucocorticoid, its efficacy in autoimmune and inflammatory disease has been established, and mechanistically it may be applicable to alopecia areata.
Alopecia areata is a T-cell mediated autoimmune attack on hair follicles, with collapse of the follicle's immune privilege. Prednisone suppresses T-cell activation and the production of pro-inflammatory cytokines, which is biologically consistent with this disease mechanism. Many of prednisone's original indications are also autoimmune or inflammatory, so the prediction fits its established pharmacological profile.
The evidence also shows limits. Systemic steroids are already used clinically for alopecia areata, but hair loss often returns after withdrawal, and cumulative steroid toxicity restricts long-term use. A 1977 follow-up of 18 patients treated with alternate-day prednisone found that the initial response did not translate into substantial long-term benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The table lists the most relevant publications, prioritising controlled trials, then reviews, then case series.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36884234 | 2023 | RCT | JAMA Dermatology | Two-step double-blind trial of methotrexate alone vs methotrexate plus low-dose prednisone in alopecia areata totalis or universalis |
| 1444500 | 1992 | Clinical trial | Archives of Dermatology | 32 patients randomised to a 6-week prednisone taper followed by 2% topical minoxidil or vehicle; compared with an open trial of 48 patients |
| 20804894 | 2010 | Clinical study | Annales de Dermatologie et de Venereologie | Efficacy and safety of once-monthly oral pulse prednisone in alopecia areata |
| 1444509 | 1992 | Review | Archives of Dermatology | Review of therapy, efficacy, safety and mechanism; study designs differ too much for meaningful comparison between drugs |
| 791152 | 1976 | Follow-up case series | Archives of Dermatology | 18 patients on alternate-day prednisone, examined about 15 months after stopping; long-term benefit not substantial, with numerous side effects |
| 37467740 | 2023 | Case series | Clinical and Experimental Dermatology | Baricitinib plus low-dose corticosteroids gave major improvement in 8 patients with very severe alopecia areata |
| 41958306 | 2026 | Retrospective case series | JEADV | Baricitinib plus low-dose prednisone in very severe alopecia areata |
| 8996277 | 1997 | Clinical evaluation | J Am Acad Dermatol | Systemic cyclosporine with low-dose prednisone in chronic severe alopecia areata |
| 38650498 | 2024 | Real-world observational study | Italian Journal of Dermatology and Venereology | Characterisation of patients hospitalised for alopecia areata in Italy: comorbidities, treatment patterns and economic burden |
| 4684625 | 1973 | Case report | Canadian Medical Association Journal | Short courses of systemic corticosteroids may suffice in alopecia totalis; relapse after stopping is not always rapid |
Note that in the 2023 RCT, prednisone was tested as an add-on to methotrexate rather than as a stand-alone treatment, so it does not directly establish the efficacy of prednisone alone.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04379P | APO-PREDNISONE TABLET 5 mg (Apotex Inc) | Tablet (oral) | Not specified in the data compiled for this report |
Safety Considerations
- Contraindication signals from the knowledge graph (not label text): The model's knowledge graph links prednisone to hypertension, congestive heart failure, hyperglycaemia, epilepsy, herpes simplex keratitis, measles, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia), and a range of pituitary hormone deficiency and hypogonadotropic hypogonadism conditions. These should be verified against the product label.
- Safety signals in the alopecia areata literature: The 1976 follow-up report noted acne, obesity, lenticular opacities and mild hypertension in patients treated with prednisone.
- Drug Interactions: 100 interactions were found. Examples include:
- Major: adalimumab
- Moderate: zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, ibuprofen, nifedipine, ethinylestradiol, butalbital, albiglutide, aldesleukin, alemtuzumab, aliskiren, tetanus toxoid vaccine
- Minor: formoterol, salbutamol
Please refer to the package insert for the full warnings and contraindications, as the label text was not available for this report.
Other Predicted Indications
| Rank | Predicted Indication | Evidence Level | Decision | Comment |
|---|---|---|---|---|
| 2 | Alopecia mucinosa | L4 | Hold | Only case reports; no prednisone-specific mechanistic evidence, and the lymphoma-associated form needs different management |
| 3 | Telogen effluvium | L5 | Hold | Usually self-limiting and non-autoimmune; no clear rationale |
| 4 | Folliculitis decalvans | L5 | Hold | Possible bacterial component not addressed by steroids; no supporting data |
| 5 | Alopecia antibody deficiency | L5 | Hold | Loosely defined entity; retrieved articles are not relevant |
| 6 | Hereditary hypotrichosis with recurrent skin vesicles | L5 | Hold | Genetic structural disorder; no rationale |
| 7 | Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | L5 | Hold | Genetic syndrome; immunosuppression unlikely to help |
| 8 | Atrichia with papular lesions | L5 | Hold | Genetic follicle regeneration disorder; not immune-driven |
| 9 | Tenosynovitis | L4 | Research Question | Glucocorticoids are used for underlying inflammatory conditions, but evidence is case reports and observational studies |
| 10 | Prolapse of lacrimal gland | L5 | Hold | Structural problem treated surgically; no evidence |
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism is biologically coherent and systemic steroids are already used for alopecia areata. However, the only randomised evidence tests prednisone as an add-on to methotrexate, with no registered clinical trials of prednisone itself, and the long-term benefit is limited by relapse and cumulative steroid toxicity. Evidence supports cautious, short-course or combination use rather than broad adoption.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently missing, and a blocking gap for safety screening)
- Detailed mechanism of action data (MOA) from DrugBank
- The approved indication text for the Singapore licence SIN04379P
- Controlled trial data on prednisone alone, including relapse rates after withdrawal
- A safety monitoring plan for long-term steroid exposure, particularly for patients with hypertension, hyperglycaemia or heart failure
- Review of interactions with concurrent therapies such as JAK inhibitors (e.g. baricitinib) used in severe disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.